Ideaya Biosciences - About the company
Ideaya Biosciences is a public company based in San Francisco (United States), founded in 2015 by Yujiro S H and Jeff Hager. It operates as a Developer of oncology-focused precision medicine using molecular diagnostics. Ideaya Biosciences has raised $157M in funding from investors like Google Ventures, Nextech Invest and Driehaus. The company has 3364 active competitors, including 1128 funded and 787 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of oncology-focused precision medicine using molecular diagnostics. The lead candidate IDE196 is a protein kinase C an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. Others include PARG, WRN, poltheta, Darovasertib, and others.
- Website
- ideayabio.com
- Registered Address
- 7000 Shoreline Court, Suite 350 South San Francisco, CA 94080
Key Metrics
Founded Year
2015
Location
San Francisco, United States
Stage
Public
Total Funding
$157M in 4 rounds
Latest Funding Round
Investors
Ranked
4th among 3364 active competitors
Employee Count
283 as on Sep 30, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Ideaya Biosciences
Ideaya Biosciences is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Ideaya Biosciences, Inc. CIN: 47-4268251 , United States, Active | Jun 10, 2015 | - | 124 (As on Dec 31, 2023) | - |
Ideaya Biosciences's IPO details
Ideaya Biosciences got listed on May 23, 2019.
Click here to take a look at Ideaya Biosciences's IPO in detail
Sign up to download Ideaya Biosciences' company profile
Ideaya Biosciences's funding and investors
Ideaya Biosciences has raised a total funding of $157M over 4 rounds. Its first funding round was on May 03, 2016. Its latest funding round was a Post IPO round on Aug 04, 2020 for $*****. 1 investor participated in its latest round. Ideaya Biosciences has 17 institutional investors.
Here is the list of recent funding rounds of Ideaya Biosciences:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 04, 2020 | 6239738 | Post IPO | 6850058 | 8931583 | 7534986 | 7869013 |
Mar 15, 2018 | 2559310 | Series B | 9190219 | 1593526 | 3783902 | |
Aug 25, 2016 | 4524262 | Series A | 8070511 | 5472035 | 4541811 |
View details of Ideaya Biosciences's funding rounds and investors
Ideaya Biosciences' founders and board of directors
Founder? Claim ProfileThe founders of Ideaya Biosciences are Yujiro S H and Jeff Hager.
Here are the details of Ideaya Biosciences' key team members:
- Yujiro S H: CoFounder & CEO of Ideaya Biosciences.
- Jeff Hager: Senior Vice President, Head of Biology and Co-Founder of Ideaya Biosciences.
View details of Ideaya Biosciences's Founder profiles and Board Members
Ideaya Biosciences' employee count trend
Ideaya Biosciences has 283 employees as of Sep 26. Here is Ideaya Biosciences's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Ideaya Biosciences's Competitors and alternates
Top competitors of Ideaya Biosciences include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Ideaya Biosciences, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd | BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd | Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 70/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th | Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 |
Looking for more details on Ideaya Biosciences's competitors? Click here to see the top ones
Ideaya Biosciences's Investments and acquisitions
Ideaya Biosciences has made no investments or acquisitions yet.
Reports related to Ideaya Biosciences
Here is the latest report on Ideaya Biosciences's sector:
News related to Ideaya Biosciences
Media has covered Ideaya Biosciences for a total of 37 events in the last 1 year, 21 of them have been about company updates and 2 about partnerships.
•
IDEAYA Biosciences Announces Promotion of Dr. Michael White to President, Research and DevelopmentPR Newswire•Sep 28, 2026•Ideaya Biosciences
•
IDEAYA's IDE849 Phase 3 Bets on What Tarlatamab Leaves Behind — the Proof Is Due in Q4Ainvest•Aug 31, 2026•Ideaya Biosciences
•
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, in Small Cell Lung CancerPR Newswire•Aug 31, 2026•Ideaya Biosciences
•
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update – News Radio KOTAAug 19, 2026•Ideaya Biosciences
•
IDEAYA Posts Q2 Loss as Cash Reaches $1.24 BillionQuiver Quantitative•Aug 04, 2026•Ideaya Biosciences
•
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy ExpanPR Newswire•Jul 27, 2026•Ideaya Biosciences
•
Flax Pond Capital LLC Makes New $1.35 Million Investment in IDEAYA Biosciences, Inc. $IDYAAmerican Banking News•Jun 20, 2026•Ideaya Biosciences
•
IDEAYA Biosciences Prices $300 Million Offering of Common Stock and Pre-Funded WarrantsPR Newswire•Jun 09, 2026•Ideaya Biosciences
•
IDEAYA Biosciences and Roche Announce Clinical Collaboration for MTAP-Deleted Pancreatic CancerPR Newswire•Jun 03, 2026•Ideaya Biosciences, Roche
•
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdatePR Newswire•May 05, 2026•Ideaya Biosciences
Are you a Founder ?
FAQs about Ideaya Biosciences
Explore our recently published companies
- My Boat Life - 2010 founded, Unfunded company
- Enlist - Unfunded company
- Parisienne - France based, Unfunded company
- ScaleDriver - Claremont based, 2016 founded, Unfunded company
- Morling - Unfunded company
- SohAI - Unfunded company